Stifel Nicolaus Cuts Insmed (NASDAQ:INSM) Price Target to $96.00

Insmed (NASDAQ:INSM) had its target price reduced by Stifel Nicolaus from $97.00 to $96.00 in a research report report published on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the company. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. Wells Fargo & Company boosted their target price on Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a report on Wednesday, February 19th. Truist Financial restated a “buy” rating and issued a $105.00 target price (up from $100.00) on shares of Insmed in a report on Friday, November 1st. Morgan Stanley boosted their target price on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Finally, JPMorgan Chase & Co. lifted their price target on Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $91.00.

Insmed Trading Down 3.0 %

Shares of INSM opened at $81.06 on Friday. The business’s 50-day moving average price is $74.29 and its 200 day moving average price is $73.61. The stock has a market capitalization of $14.50 billion, a P/E ratio of -14.50 and a beta of 1.11. Insmed has a 1-year low of $21.92 and a 1-year high of $84.91. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Analysts expect that Insmed will post -4.56 earnings per share for the current year.

Insider Activity at Insmed

In other Insmed news, CEO William Lewis sold 2,978 shares of the business’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $63.36, for a total value of $188,686.08. Following the transaction, the chief executive officer now owns 392,589 shares of the company’s stock, valued at approximately $24,874,439.04. The trade was a 0.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Martina M.D. Flammer sold 3,344 shares of the business’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total value of $220,403.04. Following the completion of the transaction, the insider now directly owns 102,766 shares in the company, valued at approximately $6,773,307.06. This represents a 3.15 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 532,207 shares of company stock valued at $41,400,465 in the last 90 days. 4.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Insmed

Several large investors have recently made changes to their positions in the company. Mackenzie Financial Corp lifted its stake in shares of Insmed by 12.5% during the fourth quarter. Mackenzie Financial Corp now owns 10,883 shares of the biopharmaceutical company’s stock valued at $751,000 after acquiring an additional 1,213 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Insmed during the fourth quarter valued at $259,000. Fourth Dimension Wealth LLC acquired a new position in shares of Insmed during the fourth quarter valued at $278,000. Vise Technologies Inc. lifted its stake in shares of Insmed by 6.3% during the fourth quarter. Vise Technologies Inc. now owns 5,634 shares of the biopharmaceutical company’s stock valued at $389,000 after acquiring an additional 336 shares during the period. Finally, Castleark Management LLC lifted its stake in shares of Insmed by 21.9% during the fourth quarter. Castleark Management LLC now owns 52,780 shares of the biopharmaceutical company’s stock valued at $3,644,000 after acquiring an additional 9,480 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.